Cardio Pod: Heart of the Matter | Podcast in RSS.com

Cardio Pod: Heart of the Matter

Cardio Pod: Heart of the Matter

di Heart Failure Collaboratory

Stagione 4

How to leverage natural history cohorts for regulatory purposes?

In this episode, host Dr. Christopher O'Connor sits down with Drs. Barry Greenberg, Marvin Konstam, and Jim Carr to discuss how to leverage natural history cohorts for regulatory purposes.

CKM Score

In this episode, host Dr. Christopher O'Connor is joined by Dr. Carine Hamo, Dr. Ankeet Bhatt, and Dr. Javed Butler to discuss the CKM Score and the quantitative methods that are beginning to transform how we design and conduct clinical trials, as well as how they can improve everyday clinical practice.

Evaluating and Accounting for Body Weight and Obesity / Adjusting for Body Weight

In this episode, host Dr. Christopher O'Connor is joined by Drs. Carine Hamo, Ankeet Bhatt, Joan Lindenfeld, and Martin Cowie to discuss the importance of evaluating and accounting for body weight and obesity in heart failure research and care. The panel explores key considerations for adjusting for body weight, interpreting clinical outcomes, and ensuring that trial design and treatment strategies accurately reflect the impact of obesity on patients with heart failure.

Derisking Phase II Clinical Trials in HF

In this episode, host Christopher O'Connor sits down with Scott D. Solomon, Ellis Unger, Janet Wittes, Michael Felker, Ben Saville, Douglas Mann, and Fady Malik to discuss how to design Phase II clinical trials that generate meaningful data, reduce uncertainty, and improve the chances of success in later-stage studies.

Class Effect considerations in devices

In this episode, Host Dr. Christopher O'Connor and his guests, Dr, Joann Lindenfeld, Dr. Mitchell Psotka, Dr. Minnow Walsh and Dr. William Abraham, discuss class effect considerations in devices.

Social Drivers of Health

In this episode, Christopher O’Connor, MD, sits down with Melvin Echols, MD; JoAnn Lindenfeld, MD; Minnow Walsh, MD; and Wayne Batchelor, MD to explore the role of social drivers of health in heart failure clinical trials. This discussion stems from an initiative of the Heart Failure Collaboratory (HFC) that led to a publication in JACC: Heart Failure titled “Social Drivers of Health in Heart Failure Trials: An Analysis from the Heart Failure Collaboratory.

Best Practices for Site-Based Research (Part 2)

This episode discusses further the challenges of site-based research. What goes into those barriers, obstacles, and opportunities to be a successful site-based researcher.

Models of Success in Site-Based Research

In this episode, Host Dr. Christopher O’Connor is joined by Dr. Melvin Echols, Dr. Anu Lala-Trindade, Dr. Maria Rosa Costanzo, Dr. Lars Kober, and Dr. Norman Stockbridge to explore key models of success in site-based research. The discussion covers operational efficiency, dedicated research infrastructure, sustainable funding and business models, collaborative partnerships, diversity and patient access, and excellence in quality and compliance.

Why is Site-Based Research Broken in the United States?

Hosted by Christopher O’Connor, MD, this episode dives into why site-based research is “broken” — fragmented, inefficient, and weighed down by administrative and regulatory burdens. Many clinical research sites — especially community hospitals and smaller practices — face inconsistent funding, delayed contract approvals, and limited infrastructure for study coordination and data management. Join Dr. O’Connor and expert guests Melvin Echols, MD; Anu Lala-Trindade, MD; Maria Rosa Costanzo, MD; Dalane Kitzman, MD, Marat Fudim, MD; and Sumeet Mitter, MD as they unpack the systemic challenges and explore how to create a more efficient, equitable research ecosystem. #HeartFailureCollaboratory #ClinicalResearch #heartfailure

Representation vs. Diversity in Clinical Trials

In this episode, host Dr. Christopher O’Connor is joined by Dr. Christian Guilliod, Dr. Wayne Batchelor, Dr. Mona Fiuzat, and Dr. Orly Vardeny to discuss the need for clinical trials to reflect the populations most affected by disease, emphasizing culturally and demographically aligned recruitment. They advocate for targeted, site-based strategies and raise concerns about interpreting results from unrepresentative samples.

1 di 3